Processa Pharmaceuticals, Inc. Common (PCSA) Dividend History

Processa Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing pharmaceutical products for serious and unmet medical conditions. The company emphasizes innovative drug development, often targeting niche markets with unmet needs, leveraging its expertise in formulation and clinical development processes.

7380 Coca Cola Drive, Hanover, MD, 21076
Phone: 443-776-3133
Website: https://www.processapharmaceuticals.com

Dividend History

Processa Pharmaceuticals, Inc. Common currently does not pay dividends

Company News

  • Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

    Processa Pharmaceuticals announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, highlighting its pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri).

    GlobeNewswire Inc.
  • Spotting Penny Stocks Uptrends, 3 Top Tips

    Here's how to spot penny stocks with potential uptrends The post Spotting Penny Stocks Uptrends, 3 Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: ACON SGBX
  • Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

    The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Abeona Therapeutics The Trade: Abeona Therapeutics Inc. (NASDAQ: ABEO) Director, Chief Executive Officer Vishwas Seshadri acquired a total of 20,000 shares ...

    Benzinga
    Featured Companies: ABEO OPK
  • Heatwurx Inc. (PCSA) Upgraded to Buy: Here's What You Should Know

    Heatwurx Inc. (PCSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Zacks Investment Research
Page data last updated 07/23/2025 16:16:25 UTC